We are live on ! Find out more
NTRP

Neurotrope, Inc. Common
NTRP

Delisted

NTRP was delisted on the 1st of December, 2020.

24 hedge funds and large institutions have $12.5M invested in Neurotrope, Inc. Common in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% more funds holding

Funds holding: 2324 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less capital invested

Capital invested by funds: $12.7M → $12.5M (-$209K)

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
10
Reduced
2
Closed
4
Calls
$133K
Puts
Net Calls
+$133K
Net Calls Change
+$133K
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
+$10 +1 New
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
+$144 +15 New

NTRP Hedge Fund Activity: Q3 2018 in Review

24 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q3 2018, worth a combined $12.5M — down 1.6% from $12.7M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NTRP positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Pathstone Family Office, opening a new position worth an estimated $293K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $80K sold.

  • 24 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q3 2018, up from 23 in Q2 2018.
  • Funds reported $12.5M of Neurotrope, Inc. Common stock for Q3 2018, down 1.6% quarter-over-quarter.
  • 5 funds opened new Neurotrope, Inc. Common positions in Q3 2018 and 4 closed out, a net change of +1 holder.
  • The largest Neurotrope, Inc. Common buyer in Q3 2018 was Pathstone Family Office, an estimated $293K added.
  • The largest Neurotrope, Inc. Common seller in Q3 2018 was JP Morgan Chase, an estimated $80K sold.

Based on aggregated 13F filings for Q3 2018.